alexa Abstract | A comparative study of efficacy and safety of rupatadine versus desloratadine in patients with chronic idiopathic urticaria

Asian Journal of Biomedical and Pharmaceutical Sciences
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Treatment of chronic idiopathic urticaria (CIU) is challenging because of its unpredictable course and negative influence on the quality of life. New treatments are being developed, but antihistaminics remain the cornerstone of the therapeutic approach. The purpose of this study was to compare the efficacy and safety of relatively new drug rupatadine with the established drug desloratadine in patients suffering from CIU. This prospective, randomized, open, outdoor-based clinical study was conducted at Department of Dermatology, Rajiv Gandhi Institute of medical sciences, Kadapa from February, 2013 to March, 2013. A total of 56 patients of CIU were randomized either to rupatadine group (n= 28) or desloratadine group (n=28). The efficacy variables were change in the total symptoms score(TSS), aerius quality of life questionnaire(AEQLQ) total score, differential count of eosinophil(DC-E), absolute eosinophil count(AEC) and serum IgE level from baseline visit to end of the study visit (after 4 weeks). Along with these the incidence of adverse effects were compared using different statistical tools. After four weeks, in rupatadine group, TSS decreased by 22.5 %( vs 10.8% in desloratadine group); AEQLQ total score decreased by 31 %( vs 17.7% in desloratadine group); AEC was decreased by 36.2% (vs 15% in desloratadine group); and serum IgE decreased by 13.3 %( vs 5.9% in desloratadine group). All the values were statistically significant (p<0.05) compared to desloratadine group. The overall incidence of adverse drug reactions was also found to be less in the rupatadine group. An analysis of the results of all the parameters of safety and efficacy proves the superiority of rupatadine over desloratadine for CIU.

To read the full article Peer-reviewed Article PDF image

Author(s): Bhanu Prakash Kolasani Raghunandan Mudium Narottam Reddy


Total symptoms score, AEQLQ total score, chronic idiopathic urticaria, rupatadine, desloratadine

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version